Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CLK3 | P49761 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 13/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414586 | 0.84 | ROCK1 (0.50) | ROCK1AURKA | |
| SCHEMBL6415974 | 0.78 | ITK (0.62) | CLK2DYRK1AITKMAPK1PIP5K1C | |
| SCHEMBL6410524 | 0.76 | ITK (0.52) | ITKALDH1A1MAPK1HSD17B10 | |
| SCHEMBL18446564 | 0.73 | CLK2 (0.87) | CLK2CLK3DYRK1AITK | |
| SCHEMBL18452512 | 0.73 | CLK2 (0.71) | CLK2CLK3DYRK1AITK | |
| SCHEMBL12895651 | 0.72 | ITK (0.48) | ITK | |
| SCHEMBL18443831 | 0.72 | WNT1 (0.75) | CLK2CLK3DYRK1A | |
| SCHEMBL3737836 | 0.70 | PARP14 (0.58) | ALDH1A1MAPK1HSD17B10IDO1 | |
| SCHEMBL18444914 | 0.69 | CLK2 (0.66) | CLK2CLK3DYRK1A | |
| SCHEMBL18444193 | 0.66 | CLK2 (1.00) | CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026984-A1 | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026984-A1 | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products | TPMT, PARK7, PRNP | CLK2 2500/4885CLK3 2957/4885DYRK1A 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.